Panel Discussion: Integrating Novel Combinations and Earlier Line Use in Diffuse Large B-Cell Lymphoma

Program Description

This in-depth discussion continues the review of novel drug classes in diffuse large B-cell lymphoma (DLBCL). Panelists will review strategies for the recognition and management of adverse effects associated with these novel agents, including evidence-based recommendations for supportive care and essential counseling points for patients. The discussion will cover emerging treatment trends, such as the potential shift of CAR T-cell therapies and bispecific antibodies into earlier lines of treatment and novel combination approaches, equipping pharmacists with the knowledge to navigate complex DLBCL management scenarios.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: September 30, 2025
Expiration date: September 30, 2026
Learner level: Foundational, Intermediate, Advanced
Time to complete activity: 0.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Explain the impact of emerging data and evolving strategies on diffuse large B-cell lymphoma (DLBCL) treatment
2. Analyze therapeutic sequencing strategies for immunotherapies in relapsed/refractory DLBCL, considering clinical evidence and real-world applications across diverse health care settings
3. Employ patient counseling strategies to optimize the safety and tolerability of DLBCL treatment and patient satisfaction
   

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-25-312-H01-P. The activity is available for CE credit through September 30, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

James A. Davis, PharmD, BCOP

Consultant: Bristol Myers Squibb, GSK, Janssen

Speakers Bureau: Janssen

Samantha Maples, PharmD, BCOP

Consultant; expert panelist for Bristol Myers Squibb

Victoria Nachar, PharmD, BCOP

Consultant: Beigene, GSK

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy L. Morris, PharmD, BCOP; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Pharmacy Times® Editorial Staff— Aislinn Antrim

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms